Evidence map›Paper›PMID 20636447›Full record

ArticleActa neurologica Scandinavica2011

EBNA1 and LMP1 variants in multiple sclerosis cases and controls.

K C Simon, X Yang, K L Munger, A Ascherio

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Acta neurologica Scandinavica, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
1.4field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 20 citations in OpenAlex.

  1. Article
  2. Sequence Variation of Epstein-Barr Virus EBNA-1 Gene in Central Nervous System Inflammatory Demyelinating Diseases in Pakistan.Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology · 2026
    Article
  3. Review
  4. Article
  5. Review
  6. Nanotechnology Frontiers in γ-Herpesviruses Treatments.International journal of molecular sciences · 2021
    Review
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Review
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

K C SimonDepartment of Nutrition, Harvard School of Public Health, Boston, MA, USA. ksimon@hsph.harvard.edu
X Yang
K L Munger
A Ascherio
Harvard University · USBrigham and Women's Hospital · US

Funding

Interdisciplinary Training in Genes and the EnvironmentT32ES016645 · NIEHS · HARVARD SCHOOL OF PUBLIC HEALTH · PI LEE, CHIH-HAO · 2008 to 2018
$4.0M
Molecular Epidemiology of EBV and Multiple SclerosisR01NS047467 · NINDS · HARVARD UNIVERSITY (SCH OF PUBLIC HLTH) · PI ASCHERIO, ALBERTO · 2005 to 2008
$2.5M
NIEHS NIH HHS T32 ES016645NIEHS NIH HHS T32 ES016645-01NINDS NIH HHS R01 NS047467NINDS NIH HHS R01 NS47467
6 · The paper itself

Abstract

backgroundPrior infection with Epstein-Barr virus (EBV) is an established risk factor for multiple sclerosis (MS). Some findings from observational studies, including possible epidemics and differences in prevalence, may be explained if different strains of EBV conferred different MS risk.

methodsDNA was extracted from peripheral lymphocytes obtained from 66 MS cases and 66 age- and cohort-matched controls. Nested polymerase chain reaction (PCR) was performed to amplify the N- and C-terminus regions of EBNA1 and the hyper-variable region of the LMP1 gene. For EBNA1, we compared the presence of the prototype B95.8 vs variant sequence and the presence of multiple strains in MS cases and controls. For LMP1, we considered differences in the proportions of mutations between cases and controls.

resultsComparing the proportion of mutant sequence between MS cases and controls in the EBNA1 N-terminal (0/28 vs 1/27) and C-terminal regions (3/40 vs 8/36) revealed no significant differences (P > 0.05). No individual variants in LMP1 were associated with risk of MS (all P > 0.05). Neither EBNA1 nor LMP1 variation was associated with anti-EBNA1 IgG antibody titers.

conclusionsThese findings do not support a strong role for variation in EBNA1 N-terminus, EBNA1 C-terminus or LMP1 contributing to MS risk.

Indexed as

AdultCase-Control StudiesEpstein-Barr Virus InfectionsEpstein-Barr Virus Nuclear AntigensFemaleGenetic VariationHerpesvirus 4, HumanHumansMiddle AgedMultiple SclerosisViral Matrix ProteinsEBV-associated membrane antigen, Epstein-Barr virusEBV-encoded nuclear antigen 1Epstein-Barr Virus Nuclear AntigensViral Matrix Proteins

Identifiers

PMID20636447
PMCPMC2965795
OpenAlexW1508678523

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.